-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, after review, the State Medical Products Administration approved the registration application
of the innovative product "intracranial aneurysm surgery plan software" produced by Qianglian Zhichuang (Beijing) Technology Co.
, Ltd.
of the innovative product "intracranial aneurysm surgery plan software" produced by Qianglian Zhichuang (Beijing) Technology Co.
, Ltd.
The product consists of application and authorization files, and the software functional modules include data loading, display interaction, data management, data processing and logging
.
The products are used for the display, segmentation, measurement and processing of X-ray angiography three-dimensional body images in patients with cerebrovascular diseases, and to assist doctors in performing microcatheter path and shaping planning
for aneurysm coil embolization during neurointerventional surgery.
.
The products are used for the display, segmentation, measurement and processing of X-ray angiography three-dimensional body images in patients with cerebrovascular diseases, and to assist doctors in performing microcatheter path and shaping planning
for aneurysm coil embolization during neurointerventional surgery.
The product uses medical image processing technology to process X-ray angiography three-dimensional tomography images of patients with intracranial aneurysms to realize three-dimensional vascular reconstruction, aneurysm segmentation and automatic measurement, as well as microcatheter path and shape planning of shaping needles, to help doctors plan before surgery
.
Compared with traditional neurointerventional surgery, the product can improve the one-time arrival rate of microcatheters, shorten the delivery time of microcatheters, reduce the probability of complications caused by repeated intraoperative microcatheters pushing on vascular stimulation, and reduce the X-ray radiation time
of doctors and patients.
.
Compared with traditional neurointerventional surgery, the product can improve the one-time arrival rate of microcatheters, shorten the delivery time of microcatheters, reduce the probability of complications caused by repeated intraoperative microcatheters pushing on vascular stimulation, and reduce the X-ray radiation time
of doctors and patients.
The drug regulatory department will strengthen the post-market supervision of the product to protect the safety
of patients' devices.
of patients' devices.
